Type 2 diabetes and metabolic syndrome in youth — structured clinical encounter

Station brief (candidate)

You are the paediatric registrar. A thirteen-year-old boy returns to the diabetes clinic for his routine review. He was diagnosed with type 2 diabetes two years ago and has been taking metformin 1000 milligrams twice daily with intermittent lifestyle adherence. His HbA1c has risen from 6.9 percent at diagnosis to 8.6 percent, his blood pressure is 134 over 88, and his urine albumin-to-creatinine ratio is mildly raised. His father and paternal grandmother both have type 2 diabetes. The team asks you to assess the trajectory, plan the escalation, address the comorbidity, and speak with the family. You have 12 minutes with the team and 5 minutes for examiner discussion. [10]

Information available on request

• Thirteen-year-old boy, type 2 diabetes for two years on metformin 1000 milligrams twice daily; lifestyle adherence intermittent. [1]
• HbA1c risen from 6.9 to 8.6 percent; body mass index at the 94th percentile; acanthosis at the neck persists. [10]
• Blood pressure 134 over 88; urine albumin-to-creatinine ratio mildly raised at 5 milligrams per millimole; lipids show triglycerides 2.1 and HDL 0.9. [11]
• Father and paternal grandmother both have type 2 diabetes; the family finds consistent lifestyle change difficult. [1]

Tasks

1. Explain why the metformin monotherapy is failing and what the TODAY trial showed about this trajectory. [10]
2. Outline the escalation of pharmacotherapy, naming the next agents, their place in the ladder, and the insulin dosing if it is needed. [1]
3. Describe the complication surveillance and the significance of the raised blood pressure and albuminuria. [11]
4. Communicate the diagnosis trajectory, the plan and the family-based approach to the family in plain language. [12]

Marking anchors

Must-hit

• Explains that beta-cell function in youth-onset type 2 diabetes declines 15 to 20 percent per year, far faster than in adults, and that TODAY showed roughly half of adolescents fail metformin monotherapy within a few years — the rising HbA1c is the expected trajectory of the disease, not an exception. [10]
• Escalates by adding a long-acting basal insulin at 0.25 to 0.5 units per kilogram per day with metformin continued, and considers a GLP-1 receptor agonist or an SGLT2 inhibitor such as empagliflozin, established in DINAMO, as add-on therapy. [1] [8]
• Recognises the blood pressure of 134 over 88 and the mildly raised albuminuria as early nephropathy and starts an ACE inhibitor or angiotensin receptor blocker, with annual complication surveillance from diagnosis. [11]

Merit

• Addresses the dyslipidaemia (triglycerides 2.1, HDL 0.9) with lifestyle and a statin where indicated from age ten, and treats the metabolic cluster as a whole rather than the glucose alone. [1]
• Frames the family as the unit of treatment, engaging the father and grandmother in the same lifestyle prescription and using the TODAY weight-change evidence to explain why weight matters for glycaemic control. [12]
• Counsels the family in plain language: this is a fast, aggressive disease, the metformin is failing because the beta cell tires more quickly in youth, and the plan is to intensify treatment now to protect the heart and kidneys over the decades ahead. [10]

Fail

• Increases the metformin dose and reviews in a year while the HbA1c, blood pressure and albuminuria continue to climb. [10]
• Watches the blood pressure and albuminuria without starting a renoprotective agent, on the grounds that the patient is young. [11]
• Tells the family that youth type 2 diabetes is mild and stable, and that no change is needed. [10]